Cerebrospinal fluid-based metabolomics to characterize different types of brain tumors

FX Wang, K Chen, FQ Huang, RN Alolga, J Ma… - Journal of …, 2020 - Springer
Background Brain tumors cause significant morbidity and mortality due to rapid progression
and high recurrence risks. Reliable biomarkers to improve diagnosis thereof are desirable …

[HTML][HTML] Tyrosine kinase inhibitors show different anti-brain metastases efficacy in NSCLC: a direct comparative analysis of icotinib, gefitinib, and erlotinib in a nude …

J Tan, M Li, W Zhong, C Hu, Q Gu, Y Xie - Oncotarget, 2017 - ncbi.nlm.nih.gov
Brain metastasis is an increasing problem in non-small cell lung cancer (NSCLC) patients.
Tyrosine kinase inhibitors (TKIs), including gefitinib, erlotinib, and icotinib, are reported to be …

Advanced lung adenocarcinoma with spinal cord metastasis successfully treated with second EGFR-TKI treatment: a case report and literature review

X Li, H Yang, J Zhao, H Gao - OncoTargets and therapy, 2015 - Taylor & Francis
Lung adenocarcinoma can be accompanied by epidermal growth factor receptor (EGFR)
mutation. As a consequence, targeted therapy based on screening of tyrosine-kinase …

[HTML][HTML] High quality of 58-month life in lung cancer patient with brain metastases sequentially treated with gefitinib and osimertinib

Y Zhang, X Zhang, F Wang, Y Feng, H Tang - Open Medicine, 2021 - degruyter.com
Brain metastases (BMs) and bone metastases seriously affect the prognosis of lung cancer
patients. How to optimize the use of existing targeted drugs is an important way to address …

[HTML][HTML] Icotinib combined whole brain radiotherapy for patients with brain metastasis from lung adenocarcinoma harboring epidermal growth factor receptor mutation

JR Li, Y Zhang, JL Zheng - Journal of Thoracic Disease, 2016 - ncbi.nlm.nih.gov
Background The brain is a metastatic organ that is most prone to lung adenocarcinoma
(LAC). However, the prognosis of patients with brain metastasis remains very poor. In this …

[HTML][HTML] Complete remission through icotinib treatment in Non-small cell lung cancer epidermal growth factor receptor mutation patient with brain metastasis: A case …

T Wang, R Wang, Z Dong, N Liang, P Chang - Open Medicine, 2016 - degruyter.com
Brain metastasis (BM) has been universally recognized as a poor prognostic factor in non-
small cell lung cancer (NSCLC). Epidermal growth factor receptor (EGFR) tyrosine kinase …

Icotinib, an EGFR-TKI, for the treatment of brain metastases in non-small cell lung cancer: a retrospective study

Q Wang, H Zheng, Y Hu, B Lu, F Hu… - Oncology and …, 2016 - journals.lww.com
Objective Treatment of brain metastases from non-small cell lung cancer (NSCLC) is a
challenge because of the poor prognosis. Icotinib is a new type of oral epidermal growth …

Opacités nodulaires diffuses et calcifiées

H Jabri, RG Bopaka, N Lakhdar, H Moubachir… - Pan African Medical …, 2016 - ajol.info
L'adénocarcinome pulmonaire est difficile à évoquer d'emblée devant les données
anamnestiques et même radiologiques. Nous rapportons une observation d'une femme …

Diffuse and calcified nodular opacities

H Jabri, RG Bopaka, N Lakhdar… - The Pan African …, 2016 - europepmc.org
Résumé L'adénocarcinome pulmonaire est difficile à évoquer d'emblée devant les données
anamnestiques et même radiologiques. Nous rapportons une observation d'une femme …

[引用][C] 肺腺癌的驱动基因突变及相应的靶向治疗

程菊, 茅矛 - 中国医药生物技术, 2016